Form 4 for KYMR Kymera Therapeutics, Inc.
Accepted 2025-12-08 00:00:00 ET · period of report 2025-12-08 · accession 0001193125-25-311504 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2025-12-08 | 2025-12-08 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $2.08 | +100.0K | 760.5K | +15% | +$208.0K |
| DT | 2025-12-08 | 2025-12-08 | KYMR | Mainolfi Nello | CEO, Dir | S - Sale+OE | $89.17 | -100.0K | 660.5K | -13% | -$8.92M |
| DT | 2025-12-08 | 2025-12-08 | KYMR | Mainolfi Nello | CEO, Dir | M - OptEx | $0.00 | -100.0K | 305.6K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-12-08 | M | A | 100,000 | $2.08 | 760,482 | D | — | — | |
| 2 | Common | Common Stock | 2025-12-08 | S | D | 100,000 | $89.17 | 660,482 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2025-12-08 | M | D | 100,000 | $0.00 | 305,559 | D | $2.08 · — to 2029-11-13 | 100,000 Common Stock | (F2) The shares underlying this stock option are fully vested and exercisable. |